Literature DB >> 36047595

Multidrug-Resistant and Extremely Drug-Resistant Pseudomonas aeruginosa in Clinical Samples From a Tertiary Healthcare Facility in Nigeria.

Amaka Marian Awanye1, Chidozie Ngozi Ibezim1, Catherine Nonyelum Stanley1, Hannah Onah1, Iheanyi Omezurike Okonko2, Nkechi Eucharia Egbe3.   

Abstract

Objectives: Pseudomonas aeruginosa has been globally implicated in healthcare-associated infection. The susceptibility pattern of clinical isolates of P. aeruginosa to anti-pseudomonal antibiotics is reported. Materials and
Methods: Clinical samples, namely blood, urine, tracheal aspirate, cerebrospinal fluid (CSF), wound swabs, high vaginal swabs, eye, and ear exudates were obtained from patients, processed and identified using standard microbiological protocols. Antibiotic susceptibility testing was undertaken using the Kirby Bauer Disc diffusion method. Results were reported following the Clinical and Laboratory Standards Institute guidelines.
Results: Of 104 P. aeruginosa isolates identified, males (52.88%) had a higher incidence of infection than female (47.11%) patients. The highest prevalence was recorded from wound swabs [46 (44.23%)] followed by ear exudates [23 (22.12%)], urine [22 (21.15%)], while eye exudates and samples from the CSF yielded the least [1 (0.96% each)]. From the antibiogram, imipenem had the highest antibiotic activity (91.3%) followed by polymyxin B (84.6%). The isolates exhibited the highest resistance to ceftazidime (73.1%) and piperacillin-tazobactam (61.5%). The antibiotic susceptibility pattern of P. aeruginosa isolates revealed 7.69% susceptible, 26% resistant, 61% multidrug resistance (MDR), 5% extremely drug resistance (XDR), and an absence (0%) of pandrug-resistant phenotypes.
Conclusion: The study recorded alarmingly high cases of MDR and some XDR phenotypes of P. aeruginosa in University of Port Harcourt Teaching Hospital. It will help identify existing gaps in antimicrobial resistance surveillance and assist in improving public health policies regarding antibiotic stewardship, initiatives, and interventions.

Entities:  

Keywords:  Antibiotics; Nigeria; Pseudomonas aeruginosa; antimicrobial resistance; extremely drug resistance; multidrug resistance

Year:  2022        PMID: 36047595      PMCID: PMC9438764          DOI: 10.4274/tjps.galenos.2021.66066

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  23 in total

Review 1.  Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.

Authors:  Zheng Pang; Renee Raudonis; Bernard R Glick; Tong-Jun Lin; Zhenyu Cheng
Journal:  Biotechnol Adv       Date:  2018-11-27       Impact factor: 14.227

Review 2.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

Review 3.  CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Authors:  Romney M Humphries; Jane Ambler; Stephanie L Mitchell; Mariana Castanheira; Tanis Dingle; Janet A Hindler; Laura Koeth; Katherine Sei
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

4.  Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria.

Authors:  Joshua T Thaden; Lawrence P Park; Stacey A Maskarinec; Felicia Ruffin; Vance G Fowler; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 6.  The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections.

Authors:  James A Driscoll; Steven L Brody; Marin H Kollef
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital.

Authors:  Nadeem Sajjad Raja; Nishi Nihar Singh
Journal:  J Microbiol Immunol Infect       Date:  2007-02       Impact factor: 4.399

Review 8.  Pseudomonas aeruginosa ventilator-associated pneumonia management.

Authors:  Sergio Ramírez-Estrada; Bárbara Borgatta; Jordi Rello
Journal:  Infect Drug Resist       Date:  2016-01-20       Impact factor: 4.003

9.  Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Bin Cai; Roger Echols; Glenn Magee; Juan Camilo Arjona Ferreira; Gareth Morgan; Mari Ariyasu; Takuko Sawada; Tsutae Den Nagata
Journal:  Open Forum Infect Dis       Date:  2017-08-16       Impact factor: 3.835

10.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.